Effect of class 3 antiarrhythmic agents on myocardium in pulmonary vein orifices

Egorov Yu.V.

doi:https://doi.org/10.17116/Cardiobulletin20211604135

Egorov Yu.V.

National Medical Research Center of Cardiology

Effect of class 3 antiarrhythmic agents on myocardium in pulmonary vein orifices

Authors:

Egorov Yu.V.

More about the authors

Journal: Russian Cardiology Bulletin. 2021;16(4): 35‑40

DOI: 10.17116/Cardiobulletin20211604135

Read: 1143 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Egorov YuV. Effect of class 3 antiarrhythmic agents on myocardium in pulmonary vein orifices. Russian Cardiology Bulletin. 2021;16(4):35‑40. (In Russ.)
https://doi.org/10.17116/Cardiobulletin20211604135

Подписка 2026 Кардиологический вестник (Russian Cardiology Bulletin)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To study the effect of class 3 antiarrhythmic agents on myocardium in pulmonary vein orifices.

MATERIAL AND METHODS

The effect of sotalol and refralone on myocardium in pulmonary vein orifices was analyzed using standard microelectrode technique. Proarrhythmic events in humans most often occur within pulmonary vein orifices.

RESULTS

We demonstrated similar augmentation of functional refractory period (FRP) at maximum therapeutic dose of both drugs (from 44±2 to 74±5 ms (p<0.001) for refralone and from 40±1 to 72±6 ms (p<0.001) for sotalol). Sotalol more significantly increase the action potential duration (from 75±3 to 101±5 ms, p<0.005) compared to refralone (from 75±1 to 85±2 ms, p<0.005) (p<0.05). Considering these data, we determined the vulnerability window (APD-FRP) and its reduction under the action of refralone (from 31±1 to 26±3 ms, 20±4 ms (p<0.05), 12±5 ms (p<0.01)). There was APD-FRP invariability under the influence of sotalol (from 35±3 to 29±5 ms, 25±6 ms, 29±7 ms).

CONCLUSION

Decrease of vulnerability window and, to a lesser extent, its shift are essential in addition to FRP increase. Perhaps, these features explain the differences in effectiveness of refralone and sotalol.

Keywords:

refralone

atrial fibrillation

action potential

functional refractory period

Authors:

Egorov Yu.V.

National Medical Research Center of Cardiology

Received:

31.03.2021

Accepted:

05.11.2021

Close metadata

References:

Ball J, Carrington MJ, McMurray JJ, Stewart S. Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. International Journal of Cardiology. 2013;167(5):1807-1824. https://doi.org/10.1016/j.ijcard.2012.12.093
Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF, Kim YH, McAnulty JH, Zheng ZJ, Forouzanfar MH, Naghavi M, Mensah GA, Ezzati M, Murray CJ. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837-847. https://doi.org/10.1161/CIRCULATIONAHA.113.005119
Wijesurendra RS, Casadei B. Mechanisms of atrial fibrillation. Heart. 2019;105(24):1860-1867. https://doi.org/10.1136/heartjnl-2018-314267
Cosío FG. Atrial Flutter, Typical and Atypical: A Review. Arrhythmia and Electrophysiology Review. 2017;6(2):55-62. https://doi.org/10.15420/aer.2017.5.2
Ludhwani D, Wieters JS. Paroxysmal Atrial Fibrillation. In: StatPearls [Internet]. Accessed May 25, 2021. https://www.ncbi.nlm.nih.gov/books/NBK535439/
Peyronnet R, Ravens U. Atria-selective antiarrhythmic drugs in need of alliance partners. Pharmacological Research. 2019;145:104262. https://doi.org/10.1016/j.phrs.2019.104262
Glushkov RG, Golitsyn SP, Dorodnikova EV, Maĭkov EB, Mashkovskiĭ MD, Merkulova IN, Rozenshtraukh LV, Ruda MIa, Skachilova SIa, Chazov EI, Iuzhakov SD. The first original Russian class-III antiarrhythmic nibentan. Vestnik Rossijskoj Akademii medicinskih nauk. 1998;11:38-41. (In Russ.).
Maykov EB, Yuricheva YA, Mironov NY, Sokolov SF, Golitsyn SP, Rosenshtraukh LV, Chazov EI. Efficacy of a new class III drug niferidil in cardioversion of persistent atrial fibrillation and flutter. Journal of Cardiovascular Pharmacology. 2014;64(3):247-55. https://doi.org/10.1097/FJC.0000000000000112
Mironov NY, Laiovich LY, Mironova ES, Sharf TV, Aparina OP, Mironova NA, Stukalova OV, Yuricheva YuA, Sokolov SF, Novikov IA, Majkov EB, Pevzner AV, Golicyn SP. New advances in the diagnosis and treatment of atrial fibrillation: from experimental studies to everyday clinical practice. Terapevticheskii arkhiv. 2019;91(6):11-18. (In Russ.). https://doi.org/10.26442/00403660.2019.06.000295
Dzaurova KhM, Mironov NYu, Yuricheva YuA, Vlodzyanovsky VV, Gagloeva DA, Laiovich LYu, Malkina TA, Zinchenko LV, Sokolov SF, Golitsyn SP. Efficiency and safety of the modified protocol for cardioversion of atrial fibrillation using domestic antiarrhythmic drug Refralon. Initial clinical results. Kardiologicheskij vestnik. 2021;16(1):49-55. (In Russ.). https://doi.org/10.17116/Cardiobulletin20211601149
Mironov NYu, Yuricheva YuA, Vlodzyanovskiy VV, Sokolov SF, Dzaurova KhM, Golitsyn SP, Shubik YuV, Berman MV, Medvedev MM, Rivin AE, Parkhomchuk DS, Barybin AE, Balandin DA, Batalov RE, Terekhov DS, Evstifeev IV, Kildeev IR, Pyataeva OV, Zenin SA. Safety and Effectiveness of Pharmacologic Conversion of Atrial Fibrillation and Flutter: Results of Multicenter Trial. Part I: Study Rationale, Design and Assessment of Effectiveness. Racional’naya farmakoterapiya v kardiologii. 2021;17(2):193-199. (In Russ.). https://doi.org/10.20996/1819-6446-2021-03-05
Kpaeyeh JA Jr, Wharton JM. Sotalol. Cardiac Electrophysiology Clinics. 2016;8(2):437-52. https://doi.org/10.1016/j.ccep.2016.02.007
Abramochkin DV, Kuzmin VS, Rosenshtraukh LV. A New Class III Antiarrhythmic Drug Niferidil Prolongs Action Potentials in Guinea Pig Atrial Myocardium via Inhibition of Rapid Delayed Rectifier. Cardiovascular Drugs and Therapy. 2017;31(5-6):525-533. https://doi.org/10.1007/s10557-017-6762-x
Haïssaguerre M, Jaïs P, Shah DC, Takahashi A, Hocini M, Quiniou G, Garrigue S, Le Mouroux A, Le Métayer P, Clémenty J. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. The New England Journal of Medicine. 1998;339(10):659-666. https://doi.org/10.1056/NEJM199809033391003
Egorov YV, Lang D, Tyan L, Turner D, Lim E, Piro ZD, Hernandez JJ, Lodin R, Wang R, Schmuck EG, Raval AN, Ralphe CJ, Kamp TJ, Rosenshtraukh LV, Glukhov AV. Caveolae-Mediated Activation of Mechanosensitive Chloride Channels in Pulmonary Veins Triggers Atrial Arrhythmogenesis. Journal of the American Heart Association. 2019;8(20):e012748. https://doi.org/10.1161/JAHA.119.012748
Egorov YV, Kuz’min VS, Glukhov AV, Rosenshtraukh LV. Electrophysiological Characteristics, Rhythm, Disturbances and Conduction Discontinuities under Autonomic Stimulation in the Rat Pulmonary Vein Myocardium. Journal of Cardiovascular Electrophysiology. 2015;26(10):1130-1139. https://doi.org/10.1111/jce.12738